Tags : Sumitomo Dainippon

PharmaShots Weekly Snapshot (September 09 – 13, 2019)

1. Eisai And Biogen to Terminate Two P-III Clinical Studies of Elenbecestat (E2609) for Early Alzheimer’s Disease Published: Sept 13, 2019 | Tags: Eisai, Biogen, Terminate Two, P-III, Clinical Studies, Elenbecestat, E2609, Early Alzheimer’s Disease 2. GE Healthcare’s Critical Care Suite AI-Powered X-ray Device Receives FDA’s 510(k) Clearance to Identify Pneumothorax Published: Sept 12, 2019 | Tags: […]Read More

Sumitomo Dainippon and Roivant Signs a Memorandum of Understanding to

Shots: Roivant to get $3B up front from Sumitomo Dainippon for selling the ownership of five of its Vant companies i.e, Myovant Sciences, Urovant Sciences, Enzyvant Therapeutics, Altavant Sciences and one is undisclosed. The agreement is expected to be signed in Oct’2019 Sumitomo to acquire >10% shares in Roivant and has an option to acquire […]Read More

Sumitomo Dainippon Reports Results of Lurasidone Hydrochloride (lurasidone) in P-III

Shots:  The P-III JEWEL Study involves assessing lurasidone (40 mg/day) vs PBO @6wks. in 483 patients with Schizophrenia, conducted for regulatory approval in Japan The P-III JEWEL Study results demonstrated the patients treated with Lurasidone responded positively; PANSS (Positive and Negative Syndrome Scale) score (-19.3 vs -12.7); AE (47.0% vs 51.1%); patients discontinued treatment (19.4% […]Read More